GEN Compiles List of Top Selling Drugs for 2012


GENGenetic Engineering & Biotechnology News has compiled a list of the top 20 best-selling prescription drugs worldwide for 2012.  GEN's list, which the journal released on March 5 (see "Top 20 Best-Selling Drugs of 2012"), was based on sales figures obtained from biopharma company press announcements, annual reports, and conference calls during 2012 and 2011.  For each drug on its list, GEN has provided 2011 and 2012 sales, percent change from 2011 to 2012, and Q4 sales and percent change for both 2011 and 2012.  2012 sales for the top 20 drugs range from $3.81 billion to $9.265 billion.  GEN's top 20 rankings are shown below, with the additional designation of small molecule or biologic for each drug that made GEN's list.

Genetic Engineering & Biotechnology News Top 20 Best-Selling Drugs of 2012

Top 20 Drugs
Genetic Engineering & Biotechnology News, "Top 20 Best-Selling Drugs of 2012," March 5, 2013.


Written by:

Published In:

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »

All the intelligence you need, in one easy email:

Great! Your first step to building an email digest of JD Supra authors and topics. Log in with LinkedIn so we can start sending your digest...

Sign up for your custom alerts now, using LinkedIn ›

* With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name.